Rituximab is actually a chimeric monoclonal antibody that binds to CD20 which is now authorized for the therapy of individuals with relapsed lower-quality lymphoma. Alemtuzumab is an anti-CD52 antibody authorized for B-CLL individuals who've unsuccessful prior therapy with FAMP. More recently FDA granted normal acceptance and expanded labeling for alemtuzumab https://connerzfkor.luwebs.com/30583678/pinometostat-for-dummies